

Malaysian Genomics 3rd Quarter FY2024 securing Revenue of RM4.48 Million, in line with Continued Growth in Biopharmaceutical Demands

PETALING JAYA, 27 NOVEMBER 2024 – **Malaysian Genomics Resource Centre Berhad** (“MGRC” or “Malaysian Genomics” or “the Group”), a leading genomics and biopharmaceutical specialist, is pleased to announce the financial performance for financial period ended 31 December 2024 (“**FY2024**”), culminating a total revenue of RM4.48 million for the cumulative 9-month period. This achievement is continuously attributed to the Group's strategic focus on cell therapies, which have contributed the majority of the Group's total revenue, demonstrating MGRC's commitment to innovation and growth in biopharmaceutical business.

Despite the dynamic market environment, MGRC has remained committed to advancing immunotherapy and cell therapy services, in addition to the organic growth of the genetic screening business. The Group's strategic endeavours, including venturing into new markets and developing novel products for the fast-moving consumer goods (“**FMCG**”) market, have been crucial in supporting the Group's vision for long-term growth and sustainability. The recent investment of equity stake in Genotec has enabled the Group to enhance its revenue through margin sales from downstream business of retail business operations.

The current quarter (“**Q3 FY2024**”) has recorded a revenue of RM1.40 million as compared to the preceding year's comparable quarter of RM2.26 million. Nonetheless, the Group has a reduction in the Loss Before Tax (“**LBT**”), from RM1.49 million in the preceding year comparable financial quarter (“**FY2023**”) to RM1.00 million in the current quarter. The increase of the LBT is largely due to increase in revenue coupled with lesser impairment loss and increased marketing for networking, brand exposure and industry presence activities.



Azri Azerai, Executive Chairman of Malaysian Genomics

Azri Azerai, Executive Chairman of Malaysian Genomics commented: "The financial outcomes for 9-months' FY2024 reflect not only our strategic focus on cell therapies and biopharmaceutical innovation but also the strength and dedication of our team. We are navigating market fluctuations with robust offerings and a clear vision.

Looking forward, MGRC is ideally positioned to spearhead the provision of genetic screening, genome analysis, and biopharmaceutical products and services across Southeast Asia.

ABOUT MALAYSIAN GENOMICS RESOURCE CENTRE BERHAD

Malaysian Genomics Resource Centre Berhad (“MGRC” or “the Group”) is a leading genomics and biopharmaceutical company based in Southeast Asia. The Group was established in 2004 and listed on the Bursa Malaysia stock exchange in 2010. From pioneering work in genome sequencing, bioinformatics analysis, and genetic screening services, MGRC has expanded into the biopharmaceutical sector with the manufacturing of cell therapies including immunotherapy for various types of cancer.

Utilising its high-throughput sequencing lab, advanced microarray facility, and new state-of-the-art cell processing lab, the Group is committed to improving access to the latest in precision and personalised healthcare solutions to improve the lives of patients.

For more information, please contact us via the following:

Website : www.mgrc.com.my

Email : enquiries@mgrc.com.my

Telephone No. : +6011 5880 4488